Ernexa
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1035 Cambridge St 18A, Cambridge, Massac...Phone Number
(617) 798-6700Website
www.ernexatx.comRevenue
-Stock Symbol
ERNAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Ernexa
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. ERNA-101 is the Companys lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The Companys initial focus is to develop ERNA-101 for the treatment of ovarian cancer.Explore more
Ernexa Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ernexa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Ernexa has new funding data
Check if Ernexa has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Ernexa had a recent Job posting/layoffs
Earning: See what the market has to say on Ernexa recently announced quarterly report
Ernexa, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Ernexa is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Ernexa
Product Launch: Get notified when Ernexa launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Ernexa is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ernexa is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ernexa.
Ernexa financials insights
Gather financial insights about Ernexa, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$15.1M
Private Equity
$40.6M
2016
Multiple Rounds
$41.6M
2020
Debt
$150K
2021
Unspecified
$20M
Stock Offering
$40.7M
2026
Stock/Share Issuance
$10.5M
Ernexa Tech Stack
A closer look at the technologies used by Ernexa
See more technologies
Most Recent Scoops
Funding
Funding
Earnings
Earnings, Finance
Project
Ernexa has approved an increase to its authorized shares of common stock from 100 million to 150 million shares.
Financial Planning, Corporate Strategy, Finance, Financial Strategy
Executive Move
Executive Moves, Video
Partnership
Project
Partnership, Product Management, Intellectual Property, Bioengineering, Medical Research, Healthcare Technology
Ernexa News & Media
Three Biotechs Deliver Catalysts to Watch
Today’s announcements from $NTHI, $ERNA, and $VIVS highlight three distinct pathways to potential value creation.Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward INDErnexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and killErnexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Ernexa
Sign Up For FreeTo access detailed company insights
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatm... Read More
